Study of GemOx and Vandetanib in Advanced Solid Malignancy
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a research study that will try to find the highest and safest dose of an experimental
drug, vandetanib, that can be given in combination with two standard chemotherapy agents,
gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.